MAPK3 and pancreatic neoplasm: In fact, MRS1220 was as effective in inhibiting phosphorylation of ERK1/2 that was triggered by pancreatic cancer cell derived membranes, as it was in inhibiting ERK1/2 phosphorylation that was induced by Cl-IBMECA, a specific agonist of the A3R (Figure 3).